Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotics Need "Societal Class" Designation To Improve Discovery, Discourage Use, Tufts Professor Tells Congress

Executive Summary

As part of its effort to encourage the development and preservation of antibiotics, FDA should consider classifying them separately from other drugs, one scientist argued

You may also be interested in...



Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets

Cubist Pharmaceuticals laid out the regulatory plan for its novel broad-spectrum cephalosporin/tazobactam combination antibiotic CXA-201 during an R&D day Sept. 20, disclosing plans to go ahead with development of the drug in hospital-acquired and ventilator-associated pneumonia

Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets

Cubist Pharmaceuticals laid out the regulatory plan for its novel broad-spectrum cephalosporin/tazobactam combination antibiotic CXA-201 during an R&D day Sept. 20, disclosing plans to go ahead with development of the drug in hospital-acquired and ventilator-associated pneumonia

Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets

The Lexington, Mass., biotech plans to start CXA-201 in HAP/VAP soon depending on how FDA guidance - due by the end of the year - plays out.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel